Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

ZacksResearch Nov. 14 at 7:06 PM

$CING gearing up for a potential 2026 catalyst — and the setup is getting interesting. 🔥 The FDA accepted the NDA for CTx-1301 with a May 31, 2026 PDUFA date, Phase 3 data hit its primary endpoint, and the company brought in a seasoned commercial leader alongside a $6M financing to prep for a potential launch. Plus, they locked in a commercial supply deal and secured a $4.3M PDUFA fee waiver — a meaningful boost to the balance sheet. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-21169&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_21169

0 · Reply

PhiloftheFuture Nov. 14 at 4:20 PM

$CADL $CING $CRSP now overweight all three. Mark 26 as the biotech awakening.

0 · Reply

BoatloadJR Nov. 14 at 2:05 PM

$CING is that all i got bears

0 · Reply

Slyfox24 Nov. 14 at 12:32 PM

$CING I’m taking advantage of this buying opportunity to load up. Us Patent will be approved very soon. After, this becomes a serious acquisition target to get bought out before the fda finalizes approval. This is the last chance to buy in at a great price. The buyout will be at least $25-40 a share or more considering how big this is going to be. They don’t just have 1 drug, when CTX-1301 gets rubber stamped by the fda soon the other drugs CING added their extended release technology to will come soon after. This company is worth much more than CTX-1301

0 · Reply

StarStripedBass77 Nov. 14 at 12:13 PM

$CING took a starter here yesterday @ 3.48

0 · Reply

Hrk024 Nov. 13 at 8:17 PM

$CING How is this a surprise to anyone? This is very common for startups like this. We essentially already have FDA approval. What is going to catapult this thing is patent news which will come out any time now. That or a buyout. Every Analyst following this thing is saying over $10/share. Some upwards to $60! Thats their reputation people! My average is $4.90 a share and im not worried at all. Just being patient like you need to be!

2 · Reply

jayhawkInvest Nov. 13 at 3:47 PM

$CING Maybe someone can better explain the 3Q results statement. It says they secured $6 MIL financing on Nov 3, then says as of Sep 30 they have enough cash to get into the 2nd Qtr, but will need $7 MIL more, and a few months back they announced a $25 MIL line with Lincoln. So how do those 3 things tie together?

1 · Reply

doublenickels55 Nov. 13 at 3:11 PM

$CING I'm a long term holder - over a year. The release today says they have enough cash runway to carry through the 2nd quarter but will need to raise an additional $7,000,000 to carry through to the FDA approval date in May 2026. There will be dillution, how that looks is TbD, but likely through a private offering (hopefully). At this point, FDA approval is almost a guarantee - CING is now a good buyout candidate at this point for some company trying to get it cheaper than waiting until after approval. I don't think they will sell.... we will see. It will definitely start working its way up by late February...

0 · Reply

DaStockman Nov. 13 at 2:43 PM

$CING https://www.cingulate.com/news-releases/news-release-details/cingulate-inc-reports-third-quarter-2025-financial-results-and

0 · Reply

activehybrid Nov. 12 at 5:55 AM

$CING today’s update short volumes up by 50 percent No dilution occurred

0 · Reply

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Sep 17, 2025, 8:45 AM EDT - 2 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Aug 21, 2025, 4:35 PM EDT - 3 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 3 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 3 months ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 3 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 5 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 6 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 7 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 8 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 11 months ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

May 12, 2023, 3:45 PM EDT - 2 years ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

ZacksResearch Nov. 14 at 7:06 PM

0 · Reply

PhiloftheFuture Nov. 14 at 4:20 PM

$CADL $CING $CRSP now overweight all three. Mark 26 as the biotech awakening.

0 · Reply

BoatloadJR Nov. 14 at 2:05 PM

$CING is that all i got bears

0 · Reply

Slyfox24 Nov. 14 at 12:32 PM

0 · Reply

StarStripedBass77 Nov. 14 at 12:13 PM

$CING took a starter here yesterday @ 3.48

0 · Reply

Hrk024 Nov. 13 at 8:17 PM

2 · Reply

jayhawkInvest Nov. 13 at 3:47 PM

1 · Reply

doublenickels55 Nov. 13 at 3:11 PM

0 · Reply

DaStockman Nov. 13 at 2:43 PM

$CING https://www.cingulate.com/news-releases/news-release-details/cingulate-inc-reports-third-quarter-2025-financial-results-and

0 · Reply

activehybrid Nov. 12 at 5:55 AM

$CING today’s update short volumes up by 50 percent No dilution occurred

0 · Reply

TheSuper Nov. 11 at 8:01 PM

$CING Hello fellas, (and ladies maybe). Looking for some thoughts on price action after PUFDA. General targets for the next week or two after that. I am having a hard time validating the price around that time. I have done DD and also read through other friends' DDs about CING, and believe this is a huge win here, especially longer term. So I am not just coming on here without researching Appreciate your thoughts and opinions.

1 · Reply

ZacksResearch Nov. 11 at 4:50 PM

$CING making moves ahead of FDA decision 👀 New Chief Commercial Officer Bryan Downey joins just after the FDA accepted the NDA for CTx-1301 and set a PDUFA target of May 31, 2026. Plus, a fresh $6M financing extends the cash runway into Q2 2026 — right through potential approval prep. 💊 See what Wall Street expects next 👉 https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-20529&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_20529

0 · Reply

Mprifold Nov. 10 at 8:23 PM

$CING I’ve never came across any stock where positive news makes the price go lower…WTF is this thing.

2 · Reply

fullobullz Nov. 10 at 3:41 PM

$CING They seem confident AF about PUFDA. They took note instead of dilution for cash, have manufacturing, distribution and sales already setup. Add US Patent grant and this will rocket

2 · Reply

activehybrid Nov. 10 at 2:27 PM

$CING $6 million note sale completed and new commercial official appointed ! Good news

1 · Reply

superdude42 Nov. 7 at 9:31 PM

$CING Dumb question, did I miss the Nov earnings report? I thought it was supposed to come out Nov 6th or 7th

3 · Reply

fullobullz Nov. 7 at 8:19 PM

$CING Anyone else think $80 may actually be in line if they get PUFDA or im I just an idiot? $CING already has patents in these countries: Australia, Canada, Israel, and Europe. Add pending US, Korea and Hong Kong and your looking at a nice market share lock. $SUPN $AXSM have mc over $1B and I think $CING could hit that as well once given pufda. Interested to hear everyone's thoughts for long term

2 · Reply

Duke1979 Nov. 7 at 1:57 PM

$CING I agree once the Patent news hits that it's being reviewed, we should see a nice spike. At some point we are going to start a nice steady climb knowing that FDA approval is as close as May. Time is ticking. If your playing this or watching this to jump in, you need to get in at these levels in my opinion. GLTA

1 · Reply

SamMusaX Nov. 6 at 3:18 AM

$CING Based on historical data for pharmaceutical and drug-delivery filings, the First Office Action is still expected between late-2025 and early-2026. Each week we get closer to Office Action. In the 16 week window we are entering week 6. There are only 10 weeks left before we see office action at a the latest! Based on historical averages for pharmaceutical filings, the First Office Action is anticipated between Oct 2025 - Jan 2026. Jan 2026 being the most likely target date. NOTE: Office Action is the beginning of the end towards the patent approval. Office Action DOES NOT mean the date the patent is issued. For anyone posting or thinking that the patent will be issued by January is wrong.

1 · Reply

SamMusaX Nov. 6 at 3:16 AM

$CING The Wednesday Weekly USA patent update. Change or no change, every Wednesday, will be posting it: Here’s the updated status for Application US 18/661,378 (Tripulse Release Stimulant Formulations), as of November 5, 2025: ________________________________________ Application US18/661,378 (Tripulse Release Stimulant Formulations) • 2024-05-10 – Application filed by Cingulate Therapeutics LLC • 2024-05-10 – Priority date established (same day as filing) • 2024-11-11 – Assignment recorded to Cingulate Therapeutics LLC (Reel/Frame 069201/0426) • 2025-02-13 – Publication of application as US 2025/0049722 A1 • 2025-11-05 (today) – Status: Pending (no Office Action issued yet; still in early prosecution phase) ________________________________________ Notes • The application remains in the early examination stage at the USPTO.

0 · Reply

fullobullz Nov. 5 at 3:34 PM

$CING Patent news anytime from now to Jan is my guess

0 · Reply

KingSwan4226 Nov. 4 at 10:25 PM

$VXRT Thank goodness I had some funds from trimming RGTI last week. Added to stocks I wanted to bring down my average on. $TOVX $CING $KLTO & of course VXRT.Is is it my phone or is stocktwits super glitchy ?

3 · Reply

Market Cap	20.57M
Revenue (ttm)	0.00
Net Income (ttm)	-15.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	222,901
Avg Vol	194,870
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	16%
Beta	-0.74
Analysts	Strong Sell
Price Target	$30.40